359 related articles for article (PubMed ID: 33841966)
1. Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB-IIIB resectable lung squamous cell carcinoma.
Shen D; Wang J; Wu J; Chen S; Li J; Liu J; Chen Q; Jiang Y
J Thorac Dis; 2021 Mar; 13(3):1760-1768. PubMed ID: 33841966
[TBL] [Abstract][Full Text] [Related]
2. The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma.
Shen D; Chen Q; Wu J; Li J; Tao K; Jiang Y
J Gastrointest Oncol; 2021 Feb; 12(1):1-10. PubMed ID: 33708420
[TBL] [Abstract][Full Text] [Related]
3. The safety and efficacy of neoadjuvant programmed death 1 inhibitor therapy with surgical resection in stage IIIA non-small cell lung cancer.
Wang J; Li J; Cai L; Chen S; Jiang Y
Ann Transl Med; 2021 Mar; 9(6):486. PubMed ID: 33850883
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of albumin-bound paclitaxel plus carboplatin as neoadjuvant therapy for potentially resectable lung squamous cell carcinoma: a real-world retrospective cohort study.
Jiang W; Zhou Y; Zeng L; Xiong Y; Liu L; Zhou C; Yang H; Guo H; Minervini F; Bongiolatti S; Yang N; Zhang Y; Tao M
Transl Lung Cancer Res; 2022 Apr; 11(4):647-655. PubMed ID: 35529791
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant pembrolizumab and chemotherapy in resectable clinical stage III non-small-cell lung cancer: a retrospective cohort study.
Zhao G; Zhang H; Xu F; Lu C; Zhu Q; Grossi F; Divisi D; Ma T; Gu J; Ge D
Transl Lung Cancer Res; 2023 Jan; 12(1):141-149. PubMed ID: 36762056
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of neoadjuvant immunochemotherapy and survival surrogate analysis of neoadjuvant treatment in IB-IIIB lung squamous cell carcinoma.
Liu J; Zhu L; Tang M; Huang X; Gu C; He C; Lv X; Hu J
Sci Rep; 2024 Mar; 14(1):5523. PubMed ID: 38448498
[TBL] [Abstract][Full Text] [Related]
7. The Safety and Efficacy of Preoperative Immunotherapy Combined with Chemotherapy in Patients with Stage IIIA-IIIB Lung Squamous Cell Carcinoma.
Wang Y; He C; Liu J; Wu S; Huang X; Zhang L; Shu W; Gu C; Wang Y; Zhu L; Hu J
Thorac Cardiovasc Surg; 2023 Apr; 71(3):222-230. PubMed ID: 36446623
[TBL] [Abstract][Full Text] [Related]
8. Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial.
Sun C; Wang X; Xu Y; Shao G; Chen X; Liu Y; Zhang P; Lin X; Ma X; Qiu S; He H; Yang Z; Ma K
EClinicalMedicine; 2024 Feb; 68():102422. PubMed ID: 38304743
[TBL] [Abstract][Full Text] [Related]
9. Clinical factors and major pathological response after neoadjuvant chemoimmunotherapy in potentially resectable lung squamous cell carcinoma.
Wang Y; Song Y; Wang R; Wu Y; Li M; Xu K; He R; Wang Z; Li Q; Kong FS; Wang T
Front Oncol; 2024; 14():1265228. PubMed ID: 38680859
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant programmed cell death protein 1 inhibitors combined with chemotherapy in resectable non-small cell lung cancer: an open-label, multicenter, single-arm study.
Duan H; Wang T; Luo Z; Tong L; Dong X; Zhang Y; Afzal MZ; Correale P; Liu H; Jiang T; Yan X
Transl Lung Cancer Res; 2021 Feb; 10(2):1020-1028. PubMed ID: 33718040
[TBL] [Abstract][Full Text] [Related]
11. Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001).
Shang X; Zhao G; Liang F; Zhang C; Zhang W; Liu L; Li R; Duan X; Ma Z; Yue J; Chen C; Meng B; Ren X; Jiang H
Ann Transl Med; 2022 Feb; 10(4):229. PubMed ID: 35280363
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma.
Yang W; Xing X; Yeung SJ; Wang S; Chen W; Bao Y; Wang F; Feng S; Peng F; Wang X; Chen S; He M; Zhang N; Wang H; Zeng B; Liu Z; Kidane B; Seder CW; Koyanagi K; Shargall Y; Luo H; Peng S; Cheng C
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35022193
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience.
Eichhorn F; Klotz LV; Kriegsmann M; Bischoff H; Schneider MA; Muley T; Kriegsmann K; Haberkorn U; Heussel CP; Savai R; Zoernig I; Jaeger D; Thomas M; Hoffmann H; Winter H; Eichhorn ME
Lung Cancer; 2021 Mar; 153():150-157. PubMed ID: 33529989
[TBL] [Abstract][Full Text] [Related]
14. [Preliminary Efficacy Evaluation of Neoadjuvant Immunotherapy Combined with
Chemotherapy in Resectable Non-small Cell Lung Cancer].
Zhou S; Hao X; Yu D; Liu S; Cao X; Su C; Song X; Xiao N; Li Y; Yang W; Zhao D; Wang J; Liu Z; Xu S
Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):420-425. PubMed ID: 34024062
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and surgical safety of sequential surgical resection after pembrolizumab plus chemotherapy for initial unresectable stage IIIB non-small cell lung cancer.
Zheng J; Li Y; Jin C; Ruan K; Sun K; Chen H; Wang M; Zhang S; Zhou J; Zhou J
Lung Cancer; 2023 Oct; 184():107326. PubMed ID: 37579576
[TBL] [Abstract][Full Text] [Related]
16. Safety and effectiveness of neoadjuvant immunotherapy combined with chemotherapy followed by surgical resection in patients with stage I-IIIA small-cell lung cancer: a retrospective single-arm clinical trial.
Liu J; Wang L; Shu W; Zhang L; Wang Y; Lv W; Zhu L; Hu J
J Thorac Dis; 2022 Nov; 14(11):4405-4415. PubMed ID: 36524062
[TBL] [Abstract][Full Text] [Related]
17. Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center.
Zhu J; Zhang Y; Wang M; Zhang Z; Yue D; Liu S; Pan Y; Wang C
Med Sci Monit; 2021 Aug; 27():e930738. PubMed ID: 34376631
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of neoadjuvant chemo-immunotherapy in non-small cell lung cancer: a real-world, multicenter, retrospective study.
Wang X; Wang X; Hui B; Cai J; Zhao H; Qiao B; Duan J; Chen K; Wang J; Lei J; Yang F
Transl Lung Cancer Res; 2024 Apr; 13(4):849-860. PubMed ID: 38736498
[TBL] [Abstract][Full Text] [Related]
19. Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell Lung cancer.
Shi L; Meng Q; Tong L; Li H; Dong Y; Su C; Liu Z
Front Oncol; 2022; 12():956755. PubMed ID: 36313678
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small cell carcinoma of the lung.
Schilder RJ; Goldberg M; Millenson MM; Movsas B; Rogatko A; Rogers B; Langer CJ
Lung Cancer; 2000 Jan; 27(1):37-45. PubMed ID: 10672782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
